Recommendation of surgical treatment in patientswith inflammatory bowel diseases – part 3: ulcerative colitis, indications for surgery

Česká verzia

Authors: Z. Šerclová ¹; O. Ryska ¹; M. Bortlík ^2,3; D. Ďuricová ^2,4 ; R. Gürlich ⁵; P. Lisý ⁵; J. Örhalmi ⁶; P. Kohout ⁷; L. Prokopová ⁸; V. Zbořil ⁸; T. Douda ⁹; P. Drastich ¹⁰ ; A. Novotný ¹¹; P. Matějková ¹²; K. Mareš ¹³; O. Shonová ¹⁴; Luděk Hrdlička ¹⁵; J. Koželuhová ¹⁶; J. Stehlík ¹⁷; M. Kasalický ¹⁸; J. Kalvach ¹⁸; J. Bronský ¹⁹; M. Tomanová ²⁰ ; M. Liberda ²¹; Přemysl Falt ²² ; M. Lukáš ^2,23
Authors place of work: Chirurgické oddělení, Nemocnice Hořovice, a. s. ¹; Klinické a výzkumné centrum pro střevní záněty ISCARE I. V. F. a. s., Praha ²; Interní klinika 1. LF UK a ÚVN Praha ³; Ústav farmakologie, 1. LF UK v Praze ⁴; Chirurgická klinika 3. LF UK a FN Královské Vinohrady, Praha ⁵; Chirurgická klinika LF UK a FN Hradec Králové ⁶; Interní oddělení, Thomayerova nemocnice, Praha ⁷; Interní gastroenterologická klinika LF MU a FN Brno ⁸; II. interní gastroenterologická klinika LF UK a FN Hradec Králové ⁹; Klinika hepatogastroenterologie, Transplantcentrum, IKEM, Praha ¹⁰; IV. interní klinika – klinika gastroenterologie a hepatologie 1. LF UK a VFN v Praze ¹¹; Gastroenterologie EGK s. r. o., Sanatorium sv. Anny, Praha ¹²; Interní oddělení, Nemocnice Na Homolce, Praha ¹³; Gastroenterologické oddělení, Nemocnice České Budějovice, a. s. ¹⁴; Gastroenterologická ambulance, Poliklinika Budějovická, Praha ¹⁵; I. interní klinika LF UK a FN Plzeň ¹⁶; Gastroenterologické oddělení, Masarykova nemocnice v Ústí nad Labem, Krajská zdravotní a. s., Ústí nad Labem ¹⁷; Chirurgická klinika 2. LF UK a ÚVN Praha ¹⁸; Pediatrická klinika 2. LF UK a FN v Motole, Praha ¹⁹; Interní oddělení, Nemocnice Jihlava, p. o. ²⁰; Gastroenterologická ambulance, Nemocnice Valašské Meziříčí, a. s. ²¹; Centrum péče o zažívací trakt, Vítkovická nemocnice a. s., Ostrava ²²; Ústav lékařské biochemie a laboratorní diagnostiky, 1. LF UK a VFN v Praze ²³
Published in the journal: Gastroent Hepatol 2016; 70(3): 252-261
Category: IBD: Guidelines
doi: https://doi.org/10.14735/amgh2015252

Summary

Ulcerative colitis is primarily treated conservatively. Surgical treatment consists of the removal of the large bowel with or without restoration of intestinal continuity. The third part of the recommendations for surgical treatment of patients with inflammatory bowel diseases addresses the indications for acute and elective surgery. The recommendations were elaborated by the Czech IBD Working Group of the Czech Society of Gastroenterology and the IBD Surgery Section of the Czech Surgical Society.

Key words:
ulcerative colitis – recommendations – indication – surgical procedures

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE „uniform requirements“ for biomedical papers.

Submitted:
3. 6. 2016

Accepted:
14. 6. 2016

Zdroje

1. Jeuring SF, Bours PH, Zeegers MP et al. Disease outcome of ulcerative colitis in an era of changing treatment strategies: results from the Dutch population--based IBDSL Cohort. J Crohns Colitis 2015; 9(10): 837– 845. doi: 10.1093/ ecco-jcc/ jjv129.

2. Bernstein CN, Ng SC, Lakatos PL et al. epidemiology and natural history task force of the International organization of the study of inflammatory bowel disease. A review of mortality and surgery in ulcerative colitis: milestones of the seriousness of the disease. Inflamm Bowel Dis 2013; 19(9): 2001– 2010. doi: 10.1097/ MIB.0b013e318281f3bb.

3. Bewtra M, Newcomb CW, Wu Q et al. Mortality associated with medical therapy versus elective colectomy in ulcerative colitis: a cohort study. Ann Intern Med 2015; 163(4): 262– 270. doi: 10.7326/ M14-0960.

4. Šerclová Z, Ryska O, Bortlík M et al. Doporučené postupy chirurgické léčby pacientů s nespecifickými střevními záněty – 1. část: předoperační příprava. Gastroent Hepatol 2015; 69(1): 12– 24. doi: 10.14735/ amgh201512.

5. Šerclová Z, Ryska O, Bortlík M et al. Doporučené postupy chirurgické léčby pacientů s nespecifickými střevními záněty – 2. část: Crohnova nemoc. Gastroent Hepatol 2015; 69(3): 223– 238. doi: 10.14735/ amgh2015223.

6.CEBM. Oxford Centre for Evidence‑-based Medicine – Levels of Evidence (March 2009). [online]. Available from: http:/ / www.cebm.net/ oxford-centre-evidence-based-medicine-levels-evidence-march-2009/ .

7. Dalkey N, Helmer O. An experimental application of the Delphi method to the use of experts. Management Science 1963; 9(3): 458– 467.

8. Øresland T, Bemelman WA, Sampietro GM et al. European Crohn᾿s and Colitis Organisation (ECCO). European evidence based consensus on surgery for ulcerative colitis. J Crohns Colitis 2015; 9(1): 4– 25. doi: 10.1016/ j.crohns.2014.08.012.

9. Dignass A, Eliakim R, Magro F et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis 2012; 6(10): 965– 990. doi: 10.1016/ j.crohns.2012.09. 003.

10. Dignass A, Lindsay JO, Sturm A et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012; 6(10): 991– 1030. doi: 10.1016/ j.crohns.2012.09.002.

11. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955; 2(4947): 1041– 1048.

12. Silverberg MS, Satsangi J, Ahmad T et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19 (Suppl A): 5A– 36A.

13. Gan SI, Beck PL. A new look at toxic megacolon: an update and review of incidence, etiology, pathogenesis, and management. Am J Gastroenterol 2003; 98(11): 2363– 2371.

14. Jalan KN, Sircus W, Card WI et al. An experience of ulcerative colitis. I. Toxic dilation in 55 cases. Gastroenterology 1969; 57(1): 68– 82.

15. Latella G, Vernia P, Viscido A et al. GI distension in severe ulcerative colitis. Am J Gastroenterol 2002; 97: 1169– 1175.

16. Strong SA. Management of acute colitis and toxic megacolon. Clin Colon Rectal Surg 2010; 23(4): 274– 284. doi: 10.1055/ s-0030-1268254.

17. Koido S, Ohkusa T, Takakura K et al. Clinical significance of serum procalcitonin in patients with ulcerative colitis. World J Gastroenterol 2013; 19(45): 8335– 8341. doi: 10.3748/ wjg.v19.i45.8335.

18. Ananthakrishnan AN , McGinley EL , Binion DG. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut 2008; 57(2): 205– 210.

19. Bitton A, Buie D, Enns R et al. Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements. Am J Gastroenterol 2012; 107(2): 179– 194. doi: 10.1038/ ajg.2011.386.

20. Gonzalez-Huix F, Fernandez-Banares F,Esteve-Comas M et al. Enteral versus parenteral nutrition as adjunct therapy in acute ulcerative colitis. Am J Gastroenterol 1993; 88(2): 227– 232.

21. Kohoutova D, Moravkova P, Kruzliak Pet al. Thromboembolic complications in inflammatory bowel disease. J Thromb Thrombolysis 2015; 39(4): 489– 498. doi: 10.1007/ s11239-014-1129-7.

22. Nguyen GC, Bernstein CN, Bitton Aet al. Consensus statements on the risk, prevention, and treatment of venous throm-boembolism in inflammatory bowel dis-ease: Canadian Association of Gastroenterology. Gastroenterology 2014; 146(3): 835– 848. doi: 10.1053/ j.gastro.2014.01.042.

23. Turner D, Walsh CM, Steinhart AH et al. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol 2007; 5(1): 103– 110.

24. Randall J, Singh B, Warren BF et al. Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications. Br J Surg 2010; 97(3): 404– 409. doi: 10.1002/ bjs.6874.

25. Travis SP, Farrant JM, Ricketts C et al. Predicting outcome in severe ulcerative colitis. Gut 1996; 38(6): 905– 910.

26. Ho GT, Mowat C, Goddard CJ et al. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment Pharmacol Ther 2004; 19(10): 1079– 1087.

27. Shibolet O, Regushevskaya E, Brezis M et al. Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev 2005; (1): CD004277.

28. Van Assche G, D᾿Haens G, Noman M et al. Randomized, double-blind comparison of 4 mg/ kg versus 2 mg/ kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003; 125(4): 1025– 1031.

29. Järnerot G, Hertervig E, Friis-Liby I et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005; 128(7): 1805– 1811.

30. Arias MT, Vande Casteele N, Ver-meire S et al. A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis. Clin Gastroenterol Hepatol 2015; 13(3): 531– 538. doi: 10.1016/ j.cgh.2014.07.055.

31. Gibson DJ, Heetun ZS, Redmond CE et al. An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol 2015; 13(2): 330– 335.e1. doi: 0.1016/ j.cgh.2014.07.041.

32. Brandse JF, van den Brink GR, Wildenberg ME et al. Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis. Gastroenterology 2015; 149(2): 350– 355. doi: 10.1053/ j.gastro.2015.04.016.

33. Laharie D, Bourreille A, Branche J et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 2012; 380(9857): 1909– 1915. doi: 10.1016/ S0140-6736(12)61084-8.

34. Laharie D, Bourreille A, Branche J et al. 829 long-term outcomes in a cohort of patients with acute severe ulcerative colitis refractory to intravenous steroids treated with cyclosporine or infliximab. Gastroenterology 2015; 148 (4 Suppl 1): S– 163. doi: 10.1016/ S0016-5085(15)30546-1.

35. Seagrove AC, Alam MF, Alrubaiy L et al. Randomised controlled trial. Comparison of infliximab and ciclosporin in steroid resistant ulcerative colitis: trial design and protocol (CONSTRUCT). BMJ Open 2014; 4(4): e005091. doi: 10.1136/ bmjopen-2014-005091.

36. Narula N, Fine M, Colombel JF et al. Systematic review: sequential rescue therapy in severe ulcerative colitis: do the benefits outweigh the risks? Inflamm Bowel Dis 2015; 21(7): 1683– 1694. doi: 10.1097/ MIB.0000000000000350.

37. Teeuwen PH, Stommel MW, Bremers AJ et al. Colectomy in patients with acute colitis: a systematic review. J Gastrointest Surg 2009; 13(4): 676– 686. doi: 10.1007/ s11605-008-0792-4.

38. Singh S, Al-Darmaki A, Frolkis AD et al. Postoperative mortality among patients with inflammatory bowel diseases: a systematic review and meta-analysis of population-based studies. Gastroenterology 2015; 149(4): 928– 937. doi: 10.1053/ j.gastro.2015.06.001.

39. Tøttrup A, Erichsen R, Sværke C et al. Thirty-day mortality after elective and emergency total colectomy in Danish patients with inflammatory bowel disease: a population-based nationwide cohort study. BMJ Open 2012; 2(2): e000823. doi: 10.1136/ bmjopen-2012-000823.

40. Roberts SE, Williams JG, Yeates D et al. Mortality in patients with and without colectomy admitted to hospital for ulcerative colitis and Crohn᾿s disease: record linkage studies. BMJ 2007; 335(7628): 1033.

41. Kaplan GG, McCarthy EP, Ayanian JZ et al. Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis. Gastroenterology 2008; 134(3): 680– 687. doi: 10.1053/ j.gastro.2008.01.004.

42. Ananthakrishnan AN, McGinley EL, Binion DG. Does it matter where you are hospitalized for inflammatory bowel disease? A nationwide analysis of hospital volume. Am J Gastroenterol 2008; 103(11): 2789– 2798. doi: 10.1111/ j.1572-0241.2008.02054.x.

43. Ferrante M, D᾿Hoore A, Vermeire Set al. Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis. Inflamm Bowel Dis 2009; 15(7): 1062– 1070. doi: 10.1002/ ibd.20863.

44. Aberra FN, Lewis JD, Hass D et al. Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology 2003; 125(2): 320– 327.

45. Sternthal MB, Murphy SJ, George Jet al. Adverse events associated with the use of cyclosporine in patients with inflammatory bowel disease. Am J Gastroenterol 2008; 103(4): 937– 943. doi: 10.1111/ j.1572-0241.2007.01718.x.

46. Powar MP, Martin P, Croft AR et al. Surgical outcomes in steroid refraktory acute severe ulcerative colitis: the impact of rescue therapy. Colorectal Dis 2013; 15(3): 374– 379. doi: 10.1111/ j.1463-1318.2012.03188.x.

47. Stewart D, Chao A, Kodner I et al. Subtotal colectomy for toxic and fulminant colitis in the era of immunosuppressive therapy. Colorectal Dis 2009; 11(2): 184– 190. doi: 10.1111/ j.1463-1318.2008.01579.x.

48. Alves A, Panis Y, Bouhnik Y et al. Subtotal colectomy for severe acute colitis: a 20-year experience of a tertiary care center with an aggressive and early surgical policy. J Am Coll Surg 2003; 197(3): 379– 385.

49. Caprilli R, Latella G, Vernia P et al. Multiple organ dysfunction in ulcerative colitis. Am J Gastroenterol 2000; 95(5): 1258– 1262.

50. Berg DF, Bahadursingh AM, Kaminski DL et al. Acute surgical emergencies in inflammatory bowel disease. Am J Surg 2002; 184(1): 45– 51.

51. Fazio VW. Toxic megacolon in ulcerative colitis and Crohn’s colitis. In: Farmer RG (ed). Clinics in gastroenterology. Philadelphia: WB Saunders 1980: 389– 407.

52. Robert JH, Sachar DB, Aufses AH et al. Management of severe hemorrhage in ulcerative colitis. Am J Surg 1990; 159(6): 550– 555.

53. Sachar DB. Management of acute, severe ulcerative colitis. J Dig Dis 2012; 13(2): 65– 68. doi: 10.1111/ j.1751-2980.2011.00560.x.

54. Greenstein AJ, Barth JA, Sachar DB et al. Free colonic perforation without dilatation in ulcerative colitis. Am J Surg 1986; 152(3): 272– 275.

55. Makkar R, Bo S. Colonoscopic perforation in inflammatory bowel disease. Gastroenterol Hepatol (NY) 2013; 9(9): 573– 583.

56. Ross H, Steele SR, Varma M et al. Practice parameters for the surgical treatment of ulcerative colitis. Dis Colon Rectum 2014; 57(1): 5– 22. doi: 10.1097/ DCR.0000000000000030.

57. Bianchi Porro G, Cassinotti A, Ferrara Eet al. Review article: the management of steroid dependency in ulcerative colitis. Aliment Pharmacol Ther 2007; 26(6): 779– 794.

58. Mowat C, Cole A, Windsor A et al. IBD Section of the British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011; 60(5): 571– 607. doi: 10.1136/ gut.2010.224154.

59. Thomas PD, Keat AC, Forbes A et al. Extraintestinal manifestations of ulcerative colitis following restorative proctocolectomy. Eur J Gastroenterol Hepatol 1999; 11(9): 1001– 1005.

60. Ott C, Schölmerich J. Extraintestinal manifestations and complications in IBD. Nat Rev Gastroenterol Hepatol 2013; 10(10): 585– 595. doi: 10.1038/ nrgastro.2013.117.

61. Heuschkel R, Salvestrini C, Beattie RM et al. Guidelines for the management of growth failure in childhood inflammatory bowel disease. Inflamm Bowel Dis 2008; 14(6): 839– 849.

62. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001; 48(4): 526– 535.

63. Lakatos L, Mester G, Erdelyi Z et al. Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: results of a population-based study. Inflamm Bowel Dis 2006; 12(3): 205– 211.

64. Bernstein CN, Blanchard JF, Kliewer E et al. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 2001; 91(4): 854– 862.

65. Watanabe T, Konishi T, Kishimoto Jet al. Ulcerative colitis-associated colorectal cancer shows a poorer survival than sporadic colorectal cancer: a nationwide Japanese study. Inflamm Bowel Dis 2011; 17(3): 802– 808. doi: 10.1002/ ibd.21365.

66. Delaunoit T, Limburg PJ, Goldberg RM et al. Colorectal cancer prognosis among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2006; 4(3): 335– 342.

67. Ording AG, Horváth-Puhó E, Erichsen Ret al. Five-year mortality in colorectal cancer patients with ulcerative colitis or Crohn᾿s disease: a nationwide population-based cohort study. Inflamm Bowel Dis 2013; 19(4): 800– 805. doi: 10.1097/ MIB.0b013e3182802af7

68. Soetikno RM, Lin OS, Heidenreich PA et al. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 2002; 56(1): 48– 54.

69. Annese V, Beaugerie L, Egan L et al. European Crohn᾿s and Colitis Organisation (ECCO). European evidence-based consensus: inflammatory bowel disease and malignancies. J Crohns Colitis 2015; 9(11): 945– 965. doi: 10.1093/ ecco-jcc/ jjv141.

70. Magro F, Langner C, Driessen A et al. European Society of Pathology (ESP); European Crohn᾿s and Colitis Organisation (ECCO). European consensus on the histopathology of inflammatory bowel disease. J Crohns Colitis 2013; 7(10): 827– 851. doi: 10.1016/ j.crohns.2013.06.001.

71. Gumaste V, Sachar DB, Greenstein AJ. Benign and malignant colorectal strictures in ulcerative colitis. Gut 1992; 33(7): 938– 941.

72. Reiser JR, Waye JD, Janowitz HD et al. Adenocarcinoma in strictures of ulcerative colitis without antecedent dysplasia by colonoscopy. Am J Gastroenterol 1994; 89(1): 119– 122.

73. Farraye FA, Odze RD, Eaden J et al. AGA institute medical position panel on diagnosis and management of colorectal neoplasia in inflammatory bowel disease. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 2010; 138(2):738– 745. doi: 10.1053/ j.gastro.2009.12.037.

74. Thomas T, Abrams KA, Robinson RJet al. Meta-analysis: cancer risk of low-grade dysplasia in chronic ulcerative colitis. Aliment Pharmacol Ther 2007; 25(6): 657– 668.

75. Choi CH, Ignjatovic-Wilson A, Askari Aet al. Low-grade dysplasia in ulcerative colitis: risk factors for developing high-grade dysplasia or colorectal cancer. Am J Gastroenterol 2015; 110(10): 1461– 1471. doi: 10.1038/ ajg.2015.248.

76. Befrits R, Ljung T, Jaramillo E et al. Low-grade dysplasia in extensive, long-standing inflammatory bowel disease: a follow-up study. Dis Colon Rectum 2002; 45(5): 615– 620.

77. Lim CH, Dixon MF, Vail A et al. Ten year follow up of ulcerative colitis patients with and without low grade dysplasia. Gut 2003; 52(8): 1127– 1132.

78. Rutter MD, Saunders BP, Wilkinson KH et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology 2006; 130(4): 1030– 1038.

79. Holm T, Ljung A, Haggmark T et al. Extended abdominoperineal resection with gluteus maximus flap reconstruction of the pelvic floor for rectal cancer. Br J Surg 2007; 94(2): 232– 238.

80. Rogler G. Chronic ulcerative colitis and colorectal cancer. Cancer Lett 2014; 345(2): 235– 241. doi: 10.1016/ j.canlet.2013.07.032.

81. Bernstein CN, Shanahan F, Weinstein WM. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? Lancet 1994; 343(8889): 71– 74.

82. Lovegrove RE, Constantinides VA, Heriot AG et al. A comparison of hand-sewn versus stapled ileal pouch anal anastomosis (IPAA) following proctocolectomy: a meta-analysis of 4183 patients. Ann Surg 2006; 244: 18– 26.

83. Andersson P, Norblad R, Soderholm JD et al. Ileorectal anastomosis in comparison with ileal pouch anal anastomosis in reconstructive surgery for ulcerative colitis – a single institution experience. J Crohns Colitis 2013; 8(7): 582– 589. doi: 10.1016/ j.crohns.2013.11.014.

84. Radice E, Nelson H, Devine RM et al. Ileal pouch-anal anastomosis in patients with colorectal cancer: long-term functional and oncologic outcomes. Dis Colon Rectum 1998; 41: 11– 17.

85. Winther KV, Jess T, Langholz E et al. Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol 2004; 2(12): 1088– 1095.